Ergothioneine: The Longevity Vitamin Hypothesis

Ergothioneine, Longevity, and Age-Related Decline

21.4-year

In a large Swedish prospective cohort tracked for over two decades, higher plasma ergothioneine was significantly associated with lower cardiovascular mortality and better overall survival.

Smith et al., Heart, 2020

1,344

Japanese adults in the Hisayama Study, followed 11.2 years for dementia outcomes

1.1 mg

estimated daily ergothioneine intake in average U.S. diets

2024

year mouse lifespan extension by ergothioneine was first demonstrated

Smith et al., Heart, 2020

View as image ↗

In 2018, biochemist Bruce Ames proposed something unusual: that ergothioneine, a sulfur compound found almost exclusively in mushrooms, might belong in the same conversation as vitamins. Not because a lack of it causes scurvy or rickets, but because chronically low levels contribute to slow, cumulative damage that characterizes aging. That proposal is now called the ergothioneine longevity vitamin hypothesis, and it has attracted serious scientific attention over the seven years since.

A 2025 Japanese study tracked 1,344 older adults for 11.2 years and found that people with higher serum ergothioneine had significantly lower rates of dementia.^[11] A 2024 animal study showed that supplementing mice with ergothioneine extended their lifespan, with mechanisms traced to FOXO transcription factors and SIRT6 upregulation.^[9] A Swedish cohort followed for a median of 21.4 years found that higher plasma ergothioneine predicted lower cardiovascular mortality.^[3]

The hypothesis is not proven. No human trial has tested whether ergothioneine supplementation extends lifespan. But the evidence converging around this compound is more substantial than most people realize, and more recent than most sources reflect. Understanding what the longevity vitamin hypothesis actually claims, and how the evidence stacks up behind it, requires following the research in the order it appeared.

For foundational background on what ergothioneine is and why the human body has a dedicated transporter for it, see Ergothioneine: The Amino Acid Your Body Hoards.

What Ames Actually Claimed: Triage Theory and the "Insidious Damage" Problem

The word "vitamin" carries a specific meaning: a compound the body cannot synthesize adequately, must obtain from diet, and whose absence causes recognizable disease. By that definition, ergothioneine is not a classical vitamin. The body does not develop scurvy without it.

What Ames proposed in 2018 was a broader framework called triage theory.^[1] The argument goes like this: when the body runs low on a micronutrient, it prioritizes survival functions over long-term maintenance. It uses available supplies to prevent immediate harm and sacrifices the slow, unglamorous work of preventing cellular aging. This triage decision is invisible in the short term. It shows up decades later, when the accumulated damage becomes disease.

Ames identified roughly 30 compounds he thought fit this pattern, things he called "longevity vitamins." Ergothioneine was one of them. The defining characteristic of a longevity vitamin, in his framing, is that deficiency doesn't look like deficiency in the short term. You don't feel sick. You don't see a lab abnormality. The damage is happening at the cellular level, slowly, over years.

This framing matters because it explains what kind of evidence is and isn't relevant. A 6-week trial showing ergothioneine improves some acute outcome doesn't test the longevity vitamin hypothesis. A 21-year cohort study tracking whether people with higher ergothioneine levels live longer does. That's why the long follow-up studies are the central evidence here.

For a deeper look at how this hypothesis developed historically, see The History of Ergothioneine: From Discovery to 'Longevity Vitamin' Debate.

The American Diet Has an Ergothioneine Gap

Beelman and colleagues published a 2020 review examining dietary ergothioneine intake patterns and their relationship to health outcomes, and they arrived at a number that anchors the deficiency argument: approximately 1.1 mg/day for average American adults.^[2]

That number is low. Ergothioneine is produced almost exclusively by fungi. Mushrooms are the only practical dietary source for most people. In countries where mushrooms feature prominently in traditional cuisine, including Japan, South Korea, and parts of Northern Europe and Italy, average dietary ergothioneine intake is substantially higher.

Beelman's review also noted that epidemiological evidence links ergothioneine intake to lower total mortality and lower neurological disease mortality, with an inverse relationship that persists across studies.^[2] The combination matters: Americans are getting very little ergothioneine, and the populations getting more of it appear to live longer and have lower rates of neurological disease.

The caveat applies here and throughout this article: high mushroom consumption correlates with other protective behaviors. Japanese diets high in mushrooms are also high in fish, fermented foods, and fiber, and low in processed foods. Untangling ergothioneine's specific contribution from the surrounding dietary pattern requires the kind of longitudinal biomarker data that the Swedish cohort and Hisayama Study provide.

For a deeper look at how the Blue Zones' traditional mushroom consumption maps onto the ergothioneine story, see Ergothioneine and the Blue Zones: A Dietary Connection?.

The Swedish Cohort: What 21 Years of Follow-Up Data Actually Shows

The most substantial human epidemiological evidence for an ergothioneine-longevity link comes from a Swedish prospective cohort reported by Smith and colleagues in 2020.^[3]

In that study, plasma ergothioneine was measured at baseline, and participants were followed for a median of 21.4 years. Higher ergothioneine at baseline was significantly associated with lower risk of coronary artery disease, lower cardiovascular mortality, and lower all-cause mortality. The association held after adjustment for standard risk factors.

The length of the follow-up is critical. Most nutritional epidemiology studies run 5 to 10 years. At 21.4 years median, this cohort is capturing outcomes that take decades to develop, which is exactly what triage theory predicts: the damage from chronic ergothioneine shortfalls accumulates slowly, and the consequences appear late. A 5-year study would likely miss most of the signal.

The geographic context also matters. Sweden has higher mushroom consumption than the United States, which means the Swedish population in this cohort had more natural variation in dietary ergothioneine levels. A population where almost no one eats mushrooms would have far less statistical power to detect ergothioneine-related effects because everyone's levels would cluster near zero.

For more detail on blood ergothioneine levels and the specific mortality findings, see Blood Ergothioneine Levels and All-Cause Mortality Risk.

Two US Mushroom Studies Point in the Same Direction

Two large studies using U.S. National Health and Nutrition Examination Survey (NHANES) data found that mushroom consumption predicted lower mortality, even in a population with comparatively low baseline ergothioneine intake.

Ba and colleagues analyzed NHANES III data and found that mushroom consumers had significantly lower all-cause mortality risk compared to non-consumers, after adjustment for standard confounders including diet quality, income, smoking, and physical activity.^[4] A separate prospective analysis of NHANES 2003-2014 data combined with a meta-analysis confirmed this pattern across multiple independent data sources.^[5]

The proposed mechanism in both studies is ergothioneine and other mushroom antioxidants. What makes this notable is that the U.S. mushroom-eating population is still getting far less ergothioneine than traditional Japanese or European diets, yet the mortality signal shows up anyway. If a reduced dietary ergothioneine intake predicts shorter survival even in a baseline low-intake population, that suggests the dose-response relationship extends to modest dietary increments.

For a focused look at this evidence, see Can Eating More Mushrooms Extend Your Lifespan? Ergothioneine Evidence.

Mouse Lifespan Extension: The Closest Thing to Proof in Animals

In 2024, Katsube and colleagues published what the longevity vitamin research had been building toward: direct evidence that ergothioneine supplementation extends lifespan in animals.^[9]

Male mice receiving 4-5 mg/kg/day ergothioneine lived significantly longer than unsupplemented controls. The researchers also tested ergothioneine in C. elegans, a roundworm commonly used in aging research because its short lifespan lets investigators observe effects within weeks rather than years. In C. elegans, ergothioneine activated FOXO transcription factors and upregulated SIRT6. Both of those are established nodes in the biology of aging. FOXO activation extends C. elegans lifespan in multiple independent contexts. SIRT6 upregulation is associated with longevity in mammals.

The mechanistic picture coheres. Earlier preclinical work from Lam-Sidun and colleagues (2021) demonstrated that ergothioneine protects against lipotoxicity, inflammatory signaling, and oxidative stress in cell and animal models, effects that are all hallmarks of accelerated cardiometabolic aging.^[7] The Katsube paper added the upstream aging pathway data: ergothioneine doesn't just mop up oxidative damage, it appears to activate the transcriptional machinery the body uses to slow aging at the cellular level.

The caveats are real. Mice are not humans. A dose of 4-5 mg/kg/day in a mouse cannot be converted to a human dose by simple multiplication because drug metabolism, body composition, and lifespan scaling differ between species. The mouse evidence tells us the mechanism works in a mammalian system and is worth pursuing in humans. It does not tell us that 10 mg/day ergothioneine will extend a human life.

The Brain Is a Special Case: What Happens When Neurons Can't Absorb Enough

Ishimoto and Kato reviewed the neuroscience of ergothioneine in 2022, and the picture they assembled explains why the age-related decline in ergothioneine has especially serious implications for cognitive health specifically.^[8]

Neurons actively accumulate ergothioneine through a transporter called OCTN1. Unlike most cell types, neurons concentrate ergothioneine to unusually high levels relative to surrounding tissue. The brain is metabolically demanding and generates substantial oxidative byproducts during normal function, so having a dedicated protective compound in reserve makes physiological sense.

The problem: OCTN1 expression in aging brains declines. This means that even if blood ergothioneine levels are maintained through diet or supplementation, neurons in older adults may absorb less of it because the uptake mechanism itself has degraded. This is a subtler issue than general antioxidant depletion. Ergothioneine has a preferred destination that becomes harder to reach as we age, independent of how much is circulating.

The comprehensive 2021 review by Cheah and Halliwell, one of the most cited authority papers in the field, synthesizes evidence for ergothioneine's protective roles against oxidative and inflammatory stress across multiple tissues, with particular attention to what happens in the absence of adequate dietary supply.^[6]

For a focused look at the OCTN1 mechanism and what its age-related decline means, see OCTN1: The Dedicated Transporter That Proves Ergothioneine Matters.

The Boldest Hypothesis in the Field: Could Low Ergothioneine Cause Neurodegeneration?

Most researchers studying ergothioneine treat the epidemiological associations as observations that warrant more investigation. In 2024, Halliwell and Cheah went further.^[10]

Their review paper directly proposed that declining ergothioneine, caused by both age-related OCTN1 decline and reduced mushroom intake in elderly populations, may be a causal contributor to neurodegenerative diseases. Not merely a biomarker that tracks alongside aging. A cause of it.

This is a hypothesis, stated clearly as one. The paper reviews the mechanistic pathway through which ergothioneine loss could drive neuronal damage, making a positive case for the causal direction. It does not present RCT evidence proving that restoring ergothioneine prevents neurodegeneration. The distinction matters.

What the paper accomplishes is a shift in the research question. "Is ergothioneine deficiency correlated with neurodegeneration?" is a descriptive question. "Does ergothioneine deficiency cause neurodegeneration, and if so, through what mechanism?" is a mechanistic question that points toward specific experiments. The Halliwell and Cheah 2024 paper is the field's most explicit statement of the second question, and it matters for understanding where the research is headed.

The Hisayama Study: 1,344 Adults, 11.2 Years, the Strongest Human Evidence Yet

In early 2025, Meng and colleagues published findings from the Hisayama Study that represent the most substantial longitudinal human evidence yet assembled for the ergothioneine-dementia link.^[11]

The study followed 1,344 community-dwelling Japanese adults aged 65 and older for a median of 11.2 years. At baseline, serum ergothioneine was measured. The primary outcomes were incident all-cause dementia, Alzheimer's disease, and non-Alzheimer's dementia. Higher serum ergothioneine was significantly associated with reduced risk across all three outcomes. The findings held after adjustment for age, sex, cardiovascular risk factors, and baseline cognitive status.

Several features make the Hisayama Study particularly credible for this hypothesis. The sample size is large for a nutritional biomarker study. The follow-up is long enough to observe late-onset cognitive outcomes that typically take years to emerge. The Japanese population context is relevant in a specific way: Japan has high traditional mushroom consumption, meaning the cohort contains people across a wider range of ergothioneine exposure than a Western cohort would. More variation in exposure gives more statistical power to detect an association.

The Hisayama Study has been running longitudinal aging research in Hisayama town since 1961, with well-characterized cohorts and systematic follow-up. This is not a convenience sample or a short-term nutritional survey. It is a deeply established population study that ergothioneine researchers can be confident has the infrastructure to support a credible 11-year follow-up.

No competitor publication has yet incorporated the Hisayama Study data into a comprehensive ergothioneine-longevity review. This study is the field's current evidence ceiling for human longitudinal data.

For the specific question of what happens when ergothioneine levels fall as people age, and what clinical outcomes follow, see Ergothioneine Declines with Age: What This Means for Health.

What Proof Would Actually Look Like

The longevity vitamin hypothesis for ergothioneine sits at an interesting evidentiary position. The epidemiological associations are real, replicated across Swedish and Japanese cohorts, and persistent over long follow-up periods. The animal lifespan data is direct and mechanistically coherent. The preclinical data offers a biological explanation for how the compound could produce these effects.

What's missing is a large, well-powered human RCT showing that ergothioneine supplementation reduces mortality or disease incidence. That kind of trial takes decades and hundreds of millions of dollars to run properly. The compounds that have such trials behind them, aspirin, statins, specific vitamin regimens, accumulated that evidence over 30 to 50 years of research effort.

Ergothioneine is perhaps 10 years into serious scientific scrutiny as a longevity-relevant compound. The 2025 Hisayama Study is a landmark, but it is still observational. What would close the loop is a randomized, placebo-controlled trial supplementing a high-risk aging population with ergothioneine over 5 to 10 years and tracking hard outcomes: dementia incidence, cardiovascular events, all-cause mortality. The pilot RCT by Yau and colleagues (2024), which tested ergothioneine in 14 mild cognitive impairment patients and saw modest but promising signals, is a first step in that direction, but 14 participants is not a trial that settles the question.

Until that evidence exists, the honest characterization of the longevity vitamin hypothesis is: compelling, mechanistically grounded, and supported by the best observational data available, but not yet proven in humans.

The Bottom Line

The ergothioneine longevity vitamin hypothesis has progressed from a theoretical framework (Ames 2018) to a position supported by decade-scale human cohort data, direct animal lifespan extension evidence, and a specific mechanistic pathway linking age-related OCTN1 decline to neuronal vulnerability. The Hisayama Study (2025) represents the field's current evidence ceiling: 1,344 Japanese adults, 11.2 years, significantly reduced dementia risk at higher ergothioneine levels. The hypothesis is not proven by human RCT, but the convergence of epidemiological, preclinical, and mechanistic evidence makes it one of the better-supported longevity hypotheses in current nutritional science.

Frequently Asked Questions

Is ergothioneine actually a vitamin?

Ergothioneine does not meet the classical definition of a vitamin because its absence does not cause an acute, recognizable deficiency disease. Bruce Ames proposed in 2018 that it belongs in a separate category called "longevity vitamins" — compounds whose chronic deficiency causes slow, cumulative aging damage that becomes visible only after years or decades. The body's dedicated transporter for ergothioneine (OCTN1) is often cited as evidence that the compound is biologically essential in some functional sense.

What is the longevity vitamin and does it work?

The "longevity vitamin" label was applied to ergothioneine by biochemist Bruce Ames in 2018, based on epidemiological links between higher ergothioneine levels and reduced mortality. A 2024 animal study (Katsube et al.) demonstrated lifespan extension in mice at 4-5 mg/kg/day via FOXO and SIRT6 activation. The 2025 Hisayama Study found significantly lower dementia risk in 1,344 Japanese adults with higher serum ergothioneine over 11.2 years. No human RCT has directly tested lifespan extension.

Does ergothioneine extend lifespan in humans?

There is no human clinical trial testing whether ergothioneine supplementation extends lifespan. Observational data shows that higher blood ergothioneine is associated with lower cardiovascular mortality in a Swedish cohort (21.4-year follow-up, Smith et al. 2020) and lower dementia incidence in a Japanese cohort (11.2-year follow-up, Meng et al. 2025). Direct lifespan extension was demonstrated in male mice and C. elegans in the 2024 Katsube study. Translating those findings to humans is not established.

What foods contain the most ergothioneine?

Mushrooms are the primary dietary source of ergothioneine, as the compound is produced almost exclusively by fungi. Within mushrooms, oyster and king oyster species typically have the highest concentrations. Shiitake, maitake, and porcini are also good sources. Ergothioneine is found in trace amounts in black beans and oats, which acquire it from fungal activity in soil. Average U.S. daily intake is estimated at approximately 1.1 mg/day, mainly from occasional mushroom consumption (Beelman et al., 2020).

How much ergothioneine do you need per day for longevity?

No established optimal daily intake for longevity in humans exists. Beelman et al. (2020) estimated U.S. average intake at 1.1 mg/day and noted this is likely below protective levels found in epidemiological associations. The Katsube mouse lifespan study used 4-5 mg/kg/day, but rodent-to-human dose translation is not straightforward. Some researchers have suggested 5-10 mg/day from dietary sources, achievable with regular mushroom consumption, as a reasonable target, but this is not a formal clinical recommendation.

Sources & References

1. 1RTHM-00936·Ames, Bruce N (2018). “Prolonging healthy aging: Longevity vitamins and proteins..” Proceedings of the National Academy of Sciences of the United States of America.Study breakdown →PubMed →↩
2. 2RTHM-01170·Beelman, Robert B et al. (2020). “Is ergothioneine a 'longevity vitamin' limited in the American diet?.” Journal of nutritional science.Study breakdown →PubMed →↩
3. 3RTHM-00655·Smith, Einar et al. (2020). “Ergothioneine is associated with reduced mortality and decreased risk of cardiovascular disease..” Heart (British Cardiac Society).Study breakdown →PubMed →↩
4. 4RTHM-00673·Ba, Djibril M et al. (2021). “Association of mushroom consumption with all-cause and cause-specific mortality among American adults: prospective cohort study findings from NHANES III..” Nutrition journal.Study breakdown →PubMed →↩
5. 5RTHM-00674·Ba, Djibril M et al. (2021). “Prospective study of dietary mushroom intake and risk of mortality: results from continuous National Health and Nutrition Examination Survey (NHANES) 2003-2014 and a meta-analysis..” Nutrition journal.Study breakdown →PubMed →↩
6. 6RTHM-00678·Cheah, Irwin K et al. (2021). “Ergothioneine, recent developments..” Redox biology.Study breakdown →PubMed →↩
7. 7RTHM-00696·Lam-Sidun, Daniel et al. (2021). “Mushroom-Derived Medicine? Preclinical Studies Suggest Potential Benefits of Ergothioneine for Cardiometabolic Health..” International journal of molecular sciences.Study breakdown →PubMed →↩
8. 8RTHM-01544·Ishimoto, Takahiro et al. (2022). “Ergothioneine in the brain..” FEBS letters.Study breakdown →PubMed →↩
9. 9RTHM-00884·Katsube, Makoto et al. (2024). “Ergothioneine promotes longevity and healthy aging in male mice..” GeroScience.Study breakdown →PubMed →↩
10. 10RTHM-01898·Halliwell, Barry et al. (2024). “Are age-related neurodegenerative diseases caused by a lack of the diet-derived compound ergothioneine?.” Free radical biology & medicine.Study breakdown →PubMed →↩
11. 11RTHM-02144·Meng, Xiangyin et al. (2025). “Serum ergothioneine and risk of dementia in a general older Japanese population: the Hisayama Study..” Psychiatry and clinical neurosciences.Study breakdown →PubMed →↩